• Je něco špatně v tomto záznamu ?

Deficient mismatch repair as a prognostic marker in stage II colon cancer patients

I. Gkekas, J. Novotny, P. Fabian, R. Nemecek, R. Palmqvist, K. Strigård, L. Pecen, T. Svoboda, R. Gurlich, U. Gunnarsson,

. 2019 ; 45 (10) : 1854-1861. [pub] 20190528

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023623

BACKGROUND: A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact prognostic role of dMMR has not been clearly established due to contradictory results. This study aims to determine the prognostic impact of dMRR in stage II colon cancer patients only. The appropriate identification of high-risk stage II colon cancers is of paramount importance in the selection of patients who may benefit from adjuvant treatment after surgery. METHODS: Four hundred and fifty-two patients with curative resection of stage II colon cancer were included. Hospital records were used as data source, providing clinical, surgical, pathology, oncology and follow-up information for statistical analysis focusing on overall survival (OS) and time to progression (TTP). Mismatch repair status was determined by immunohistochemistry. Patient survival was followed-up for a mean of 77·35 months. RESULTS: dMMR was detected in 93 of 452 patients (20·6%). No impact on overall survival (Log-Rank, p = 0·583, 95% CI 0·76-1·67). However, the hazard ratio 0·50 for TTP was highly significant (Log-Rank, p = 0·012, 95% CI 0·28-0·87) in patients with dMMR compared with those with mismatch repair proficient tumours (pMMR). CONCLUSIONS: Patients with dMMR tumours have a lower risk for recurrence compared to those with pMMR tumours, but this finding did not correlate to better overall survival.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023623
003      
CZ-PrNML
005      
20201214130632.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejso.2019.05.023 $2 doi
035    __
$a (PubMed)31186203
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Gkekas, Ioannis $u Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden. Electronic address: ioannis.gkekas@nll.se.
245    10
$a Deficient mismatch repair as a prognostic marker in stage II colon cancer patients / $c I. Gkekas, J. Novotny, P. Fabian, R. Nemecek, R. Palmqvist, K. Strigård, L. Pecen, T. Svoboda, R. Gurlich, U. Gunnarsson,
520    9_
$a BACKGROUND: A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact prognostic role of dMMR has not been clearly established due to contradictory results. This study aims to determine the prognostic impact of dMRR in stage II colon cancer patients only. The appropriate identification of high-risk stage II colon cancers is of paramount importance in the selection of patients who may benefit from adjuvant treatment after surgery. METHODS: Four hundred and fifty-two patients with curative resection of stage II colon cancer were included. Hospital records were used as data source, providing clinical, surgical, pathology, oncology and follow-up information for statistical analysis focusing on overall survival (OS) and time to progression (TTP). Mismatch repair status was determined by immunohistochemistry. Patient survival was followed-up for a mean of 77·35 months. RESULTS: dMMR was detected in 93 of 452 patients (20·6%). No impact on overall survival (Log-Rank, p = 0·583, 95% CI 0·76-1·67). However, the hazard ratio 0·50 for TTP was highly significant (Log-Rank, p = 0·012, 95% CI 0·28-0·87) in patients with dMMR compared with those with mismatch repair proficient tumours (pMMR). CONCLUSIONS: Patients with dMMR tumours have a lower risk for recurrence compared to those with pMMR tumours, but this finding did not correlate to better overall survival.
650    _2
$a adenokarcinom $x diagnóza $x genetika $x metabolismus $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádory tračníku $x diagnóza $x genetika $x terapie $7 D003110
650    _2
$a kombinovaná terapie $7 D003131
650    12
$a oprava chybného párování bází DNA $7 D053843
650    _2
$a DNA nádorová $x genetika $7 D004273
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Novotny, Jan $u Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
700    1_
$a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Nemecek, Radim $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Palmqvist, Richard $u Department of Medical Biosciences/Pathology, Umeå University, Umeå, Sweden.
700    1_
$a Strigård, Karin $u Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
700    1_
$a Pecen, Ladislav $u Faculty Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Svoboda, Tomas $u Faculty Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Gurlich, Robert $u Department of Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Gunnarsson, Ulf $u Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
773    0_
$w MED00005360 $t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology $x 1532-2157 $g Roč. 45, č. 10 (2019), s. 1854-1861
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31186203 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130631 $b ABA008
999    __
$a ok $b bmc $g 1595942 $s 1114299
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 45 $c 10 $d 1854-1861 $e 20190528 $i 1532-2157 $m European journal of surgical oncology $n Eur J Surg Oncol $x MED00005360
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace